Individual differences in equol production capability modulate blood pressure in tibolone-treated postmenopausal women: Lack of effect of soy supplementation

Climacteric

Volumn 10, Issue 6, 2007, Pages 471-479

  Tormala R M ^a   Appt, S ^b   Clarkson, T B ^b   Tikkanen, M J ^a   Ylikorkala, O ^a   Mikkola, T S ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular; Clinical Trial; Isoflavones; Phytoestrogens

Indexed keywords

EQUOL; GENISTEIN; PLACEBO; SOYBEAN PROTEIN; TIBOLONE;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EDEMA; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; HUMAN; MEAN ARTERIAL PRESSURE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOYBEAN MILK; STOMACH PAIN; SYSTOLIC BLOOD PRESSURE; VAGINA BLEEDING;

BLOOD PRESSURE; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENISTEIN; HUMANS; ISOFLAVONES; MALE; MIDDLE AGED; NORPREGNENES; PHYTOESTROGENS; POSTMENOPAUSE; SOYBEAN PROTEINS; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 36749022315     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701624971     Document Type: Article

References (35)

1. Adlercreutz H. Phytoestrogens and breast cancer. J Steroid Biochem Mol Biol 2003;83:113-18
2. Clarkson TB. Soy, soy phytoestrogens and cardiovascular disease. J Nutr 2002;132:566-9S
3. Murkies AL, Wilcox G, Davis SR. Phytoestrogens. J Clin Endocrinol Metab 1998;83:297-303
4. Erdman JW. Soy protein and cardiovascular disease: a statement for healthcare professionals from the nutrition committee of the AHA. Circulation 2000;102:2555-9
5. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M, for the American Heart Association Nutrition Committee. Soy Protein, Isoflavones, and Cardiovascular Health: An American Heart Association Science Advisory for Professionals From the Nutrition Committee. Circulation 2006;113:1034-44
6. Dewell A, Hollenbeck PL, Hollenbeck CB. Clinical review: a critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations. J Clin Endocrinol Metab 2006;91:772-80
7. Gu L, House SE, Prior RL, et al. Metabolic phenotypes of isoflavones differ among female rats, pigs, monkeys, and women. J Nutr 2006;136:1215-21
8. Setchell KDR, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol - a clue to the effectiveness of soy and its isoflavones. J Nutr 2002;132:3577-84
9. Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med 2005;230:155-70
10. Duncan AM, Merz-Demlow BE, Xu X, Phipps WR, Kurzer MS. Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2000;9:581-6
11. Frankenfeld CL, McTiernan A, Tworoger SS, et al. Serum steroid hormones, sex hormone-binding globulin concentrations, and urinary hydroxylated estrogen metabolites in postmenopausal women in relation to daidzein- metabolizing phenotypes. J Steroid Biochem Mol Biol 2004;88:399-408
12. Atkinson C, Berman S, Thomas W, Lampe J. The in vitro metabolism of estrogens by human fecal bacteria: a comparison of equol-producers and non-producers. J Nutr 2007; in press
13. Speroff L, Clarkson TB. Is tibolone a viable alternative to HT? Contemporary Ob/Gyn 2003;2-11
14. Kenemans P, Speroff L, for the International Tibolone Consensus Group. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005;51:21-8
15. Vos RM, Krebbers SF, Verhoeven CH, Delbressine LP. The in vivo human metabolism of tibolone. Drug Metab Dispos 2002;30:106-12
16. Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE. Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 2006;119:133-41
17. Törmälä RM, Nikander E, Tiitinen A, Väisänen- Tommiska M, Ylikorkala O, Mikkola TS. Serum cholesterol efflux potential in postmenopausal women treated with isolated isoflavones. Menopause 2006;13:96-101
18. Verheul HA, Blok LJ, Burger CW, Hanifi-Moghaddam P, Kloosterboer HJ. Levels of tibolone and estradiol and their nonsulfated and sulfated metabolites in serum, myometrium and vagina of postmenopausal women treated for 21 days with tibolone, estradiol or estradiol plus medroxyprogesteroneacetate. Reprod Sci 2007;14:160-8
19. Mueck AO, Seeger H. Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women. Maturitas 2004;49:189-203
20. Cagnacci A, Baldassari F, Arangino S, Alessandrini C, Volpe A. Administration of tibolone decreases 24 h heart rate but not blood pressure of post-menopausal women. Maturitas 2004;48:155-60
21. Setchell KD, Borriello SP, Hulme P, Kirk DN, Axelson M. Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am J Clin Nutr 1984;40:569-78
22. 13C- labeled tracers in premenopausal women. Am J Clin Nutr 2003;77:411-19
23. Grace PB, Taylor JI, Low YL, et al. Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutrition-norfolk. Cancer Epidemiol Biomarkers Prev 2004;13:698-708
24. Chin-Dusting JPF, Fisher LJ, Lewis TV, Piekarska A, Nestel PJ, Husband A. The vascular activity of some isoflavone metabolites: implications for a cardioprotective role. Br J Pharmacol 2001;133:595-605
25. Giménez I, Lou M, Vargas F, et al. Renal and vascular actions of equol in the rat. J Hypertension 1997;15:1303-8
26. Setchell KDR, Clerici C, Lephart ED, et al. S-Equol, a potent ligand for estrogen receptor b, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by the human bacterial flora. Am J Clin Nutr 2005;81:1072-9
27. Kloosterboer JH. Tissue-selectivity: the mechanism of action of tibolone. Maturitas 2004;48:S30-40
28. Harris RM, Wood DM, Bottomley L, et al. Phytoestrogens are potent inhibitors of estrogen sulfation: implications for breast cancer risk and treatment. J Clin Endocrinol Metab 2004;89:1779-87
29. Kreijkamp-Kaspers S, Kok L, Bots ML, Grobbee DE, Lampe JW, van der Schouw YT. Randomized controlled trial of the effects of soy protein containing isoflavones on vascular function in postmenopausal women. Am J Clin Nutr 2005;81:189-95
30. Dalais FS, Ebeling PR, Kotsopoulos D, McGrath BP, Teede HJ. The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women. Clin Endocrinol 2003;58:704-9
31. Tham DM, Gardner CD, Haskell WL. Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological and mechanistic evidence. J Clin Endocrinol Metab 1998;83:2223-35
32. Rivas M, Garay RP, Escanero JF, Cia Jr P, Cia P, Alda JO. Soy milk lowers blood pressure in men and women with mild to moderate essential hypertension. J Nutr 2002;132:1900-2
33. Kotsopoulos D, Dalais FS, Liang YL, McGrath BP, Teede HJ. The effects of soy protein containing phytoestrogens on menopausal symptoms in postmenopausal women. Climacteric 2000;3:161-7
34. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM; American Heart Association. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 2006;47:296-308
35. Miller ER 3rd, Jehn ML. New high blood pressure guidelines create new at-risk classification: changes in blood pressure classification by JNC 7. J Cardiovasc Nurs 2004;19:367-71